Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay

Invest New Drugs. 2012 Aug;30(4):1750-5. doi: 10.1007/s10637-011-9688-3. Epub 2011 May 21.

Authors

Sarah Schott¹, Markus Wallwiener, Beate Kootz, Harald Seeger, Tanja Fehm, Hans Neubauer

Affiliation

¹ Department of Gynaecology and Obstetrics, National Center for Tumour Diseases, University of Heidelberg, 69115 Heidelberg, Germany.

PMID: 21604021
DOI: 10.1007/s10637-011-9688-3

No abstract available

Publication types

Comparative Study

MeSH terms

Adenosine Triphosphate / metabolism
Alendronate / analogs & derivatives*
Alendronate / chemistry
Alendronate / pharmacology
Alendronate / therapeutic use
Antimetabolites, Antineoplastic / chemistry
Antimetabolites, Antineoplastic / pharmacology*
Antimetabolites, Antineoplastic / therapeutic use
Breast Neoplasms / drug therapy
Breast Neoplasms / pathology*
Cell Death / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Diphosphonates / chemistry
Diphosphonates / pharmacology*
Diphosphonates / therapeutic use
Drug Screening Assays, Antitumor
Female
Fluorouracil / analogs & derivatives*
Fluorouracil / chemistry
Fluorouracil / pharmacology
Fluorouracil / therapeutic use
Humans
Imidazoles / pharmacology
Imidazoles / therapeutic use
Inhibitory Concentration 50
Ovarian Neoplasms / drug therapy
Ovarian Neoplasms / pathology*
Reference Standards
Zoledronic Acid

Substances

5-FdU-alendronate
Antimetabolites, Antineoplastic
Diphosphonates
Imidazoles
Zoledronic Acid
Adenosine Triphosphate
Fluorouracil
Alendronate